Literature DB >> 15798559

[Bullous pemphigoid in young patients: a retrospective study of 74 cases].

E Bourdon-Lanoy1, J-C Roujeau, P Joly, J-C Guillaume, P Bernard, C Prost, E Tancrède-Bohin, E Delaporte, C Picard-Dahan, B Albes, C Bedane, M-S Doutre, O Chosidow, C Lok, C Pauwels, J Chevrand-Breton, B Sassolas, M-A Richard.   

Abstract

INTRODUCTION: Bullous pemphigoid usually affects elderly people. Only a few isolated cases among people younger than 65 years have been reported.
OBJECTIVES: Describe the clinical and biological characteristics of patients younger than 60 years suffering from bullous pemphigoid, compare them with the usual characteristics known among elderly people and search for potential pathological associations. PATIENTS AND METHODS: Retrospective, national, multicenter study. Clinical, biological and histological characteristics were recorded with a standardised questionnaire as well as treatments and associated pathologies.
RESULTS: Seventy-four cases of bullous pemphigoid diagnosed between June 1970 and March 2002 were analyzed. Mean age at the beginning of the disease was 46 +/- 11.6 years. Further explorations by indirect immunofluorescence of separated skin and/or immuno-electron microscopy and/or immunoblotting were performed for 42 patients (56.8 p. 100). Clinical characteristics among this restricted population were comparable to those found among the 32 other cases. Compared to usual data on bullous pemphigoid in elderly people, we observed a greater proportion of extensive form of disease (75 p. 100), a more frequent head and neck involvement (39.2 p. 100) and an overexpression of anti-BP180 autoantibodies (48 p. 100). Neoplasm was notified for 7 patients (9.5 p. 100), 18 (24.3 p. 100) suffered from a pathology of the basement membrane zone (6 psoriasis, 6 atopic dermatitis and 6 lichen) and 13 from neurological disease, among which 4 were bedridden. Fourty-six patients (62.2 p. 100) received drugs for the long term (mean 2.12 +/- 2.43), 4 patients were treated by PUVAtherapy and 2 by radiotherapy. DISCUSSION: Our results suggest that bullous pemphigoid among young people is more severe and more active than the usual form in the elderly. This particular form could be the result of a higher expression of anti-BP180 autoantibodies, which are considered as a marker of poor prognosis in this disease. We also found a high frequency of pathological associations and physical treatment, all responsible for damage to the basement membrane zone, which can involve auto-immunization against hemidesmosome components.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15798559     DOI: 10.1016/s0151-9638(05)79220-6

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  6 in total

1.  [A severe course of bullous pemphigoid in a young man].

Authors:  S Eigelshoven; D Bruch-Gerharz; E Enderlein; T Ruzicka; A S Büchau; M Hertl; J Reifenberger; K-W Schulte
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

2.  A Systematic Review of Drug-Induced Pemphigoid.

Authors:  Matthew J Verheyden; Asli Bilgic; Dédée F Murrell
Journal:  Acta Derm Venereol       Date:  2020-08-17       Impact factor: 3.875

Review 3.  Interaction of Psoriasis and Bullous Diseases.

Authors:  Teruki Dainichi; Kenji Kabashima
Journal:  Front Med (Lausanne)       Date:  2018-08-08

4.  A case series of ocular involvement in bullous pemphigoid: clinical features, management, and outcomes.

Authors:  Anahita Kate; Swapna Shanbhag; Pragnya Rao Donthineni; Sayan Basu
Journal:  F1000Res       Date:  2021-11-25

5.  A Cross-Sectional Study to Correlate Disease Severity in Bullous Pemphigoid Patients with Serum Levels of Autoantibodies Against BP180 and BP230.

Authors:  Naziya Muhammed; Seema Korgaonkar; Vandana Pradhan; Uday S Khopkar
Journal:  Indian Dermatol Online J       Date:  2021-09-10

Review 6.  Collagen XVII: a shared antigen in neurodermatological interactions?

Authors:  Allan Seppänen
Journal:  Clin Dev Immunol       Date:  2013-06-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.